Similarly, olaparib treatment reduced the granulocyte component of the MDSC population in a mouse model of breast cancer susceptibility genes 1 (BRCA1)-deficient ovarian cancer [20]. This evidence concerns the gene BRCA1 and ovarian carcinoma.